Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low – Here’s Why

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) reached a new 52-week low during trading on Saturday . The company traded as low as $18.85 and last traded at $19.37, with a volume of 450718 shares traded. The stock had previously closed at $20.99.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price target on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $48.00 price target on the stock. Evercore assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, William Blair began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Price Performance

Insider Buying and Selling

In other Kailera Therapeutics news, Director Adam Koppel bought 1,562,500 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the director directly owned 22,583,268 shares of the company’s stock, valued at $361,332,288. This trade represents a 7.43% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Andrew T. Kaplan bought 8,398,438 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares in the company, valued at approximately $420,089,296. This represents a 47.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 10,460,938 shares of company stock worth $167,375,008 in the last ninety days.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.